Partnership strengthens Glenmark’s oncology strategy across high-potential markets
Glenmark Specialty, a wholly owned subsidiary of Glenmark Pharmaceuticals, has entered into an exclusive license, collaboration and distribution agreement with Jiangsu Hansoh Pharmaceutical Group Co, (Hansoh Pharma) for Aumolertinib, a third-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) for the treatment of non-small cell lung cancer (NSCLC).
Under the terms of the agreement, Glenmark receives exclusive rights to develop and commercialize Aumolertinib across its licensed territories: Middle East and Africa, Southeast & South Asia, Australia, New Zealand, Russia/CIS and a few selected Caribbean countries covered by the agreement. Hansoh Pharma will receive an upfront payment of low double-digit million USD, followed by potential regulatory and commercial milestone payments possibly cumulating to over US$1 billion, in addition to tiered royalties on net sales in the licensed territories.
“At Glenmark, we remain focussed on building a growth-oriented oncology business across high-potential markets. Aumolertinib is a strategic addition that strengthens our near-term commercial pipeline and enhances our ability to serve patients with EGFR-mutated lung cancer. This collaboration reinforces our disciplined approach to expanding our innovative portfolio and widening access to advanced cancer care across key markets,” said Glenn Saldanha, Chairman and Managing Director, Glenmark Pharmaceuticals.
Aumolertinib, (marketed as Ameile in China and Aumseqa in the UK and Europe), as a monotherapy, has received marketing authorization from the UK MHRA and is indicated the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations, and the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC. It has also received approval for four indications in China (second-line T790M mutation, first-line NSCLC EGFR mutated, unresectable Stage III post-chemoradiotherapy, and adjuvant Stage II–IIIB NSCLC). Aumolertinib became Hansoh Pharma’s first innovative drug approved in an overseas market and the first China-developed EGFR-TKI to be launched internationally.
